Johnson & Johnson reported a 7.5 percent drop in orthopedic sales during the first quarter of 2020, disrupted by the coronavirus.
In many places around the U.S. and across the world, surgeons are canceling or postponing elective procedures to save resources for those treating COVID-19 patients and stem the spread of the virus. As a result, orthopedic companies across the board are seeing lower sales and adjusting their financial outlook.
Five things to know about Johnson & Johnson orthopedic sales:
1. U.S. orthopedics sales were down 5.2 percent to $1.2 billion for the first quarter, while international sales dropped 11 percent. Overall, orthopedic sales were 7.5 percent lower for the first quarter of 2020 than 2019, hitting $2 billion.
2. Hip sales dropped 6.7 percent overall to $337 million for the quarter. International hip sales were down 11.2 percent and U.S. sales dropped 3.6 percent quarter-over-quarter, hitting $206 million.
3. Worldwide knee sales were 7 percent lower in the first quarter of 2020 than 2019, dropping 4.2 percent in the U.S. and 11.4 percent internationally. The company reported $343 million in knee sales for the quarter overall.
4. Trauma sales in the U.S. were down 2.3 percent, hitting $207 million. Internationally, trauma sales dropped 8 percent and overall trauma sales hit $654 million, a 4.5 percent decrease.
5. Worldwide spine, sports and other sales were down 10.7 percent for the quarter, hitting $702 million. U.S. sales dropped 8.9 percent and international sales were down 13.3 percent.